A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Recruiting · NCT02889666 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
CarboplatinCisplatinDocetaxelDocetaxel/CarboplatinDocetaxel/OxaliplatinGemcitabine/CarboplatinGemcitabine/CisplatinPlacebo
What this trial is about
The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≤ 75 years with histologically proven NSCLC
- No severe major organ dysfunction
- WHO performance status of 0 or 1
- No prior cancer chemotherapy
- A Clinical Stage ≥ IA (T1a, N0, M0) of lung disease but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer TNM staging system) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.
Exclusion criteria
- Age ≥ 76
- Severe major organ dysfunction
- WHO performance status of \>1
- Prior cancer chemotherapy
- Stage IV
Where it is running
3 locations listed.
- Shanghai 10th People's Hospital - Shanghai, China
- Shanghai Pulmonary Hospital, Tongji University School of Medicine - Shanghai, China
- China-Japan Union Hospital, Jilin University - Changchun, Jilin, China